Skip to main content

Liposomal Bupivacaine (Exparel)

Liposomal bupivacaine is a multivesicular-liposomal formulation of bupivacaine designed to release drug over up to 72 hours from a single injection — theoretically an ideal ERAS adjunct for wound infiltration and peripheral / fascial-plane blocks. The evidence has not supported the theory. Across 76+ RCTs reviewed in a comprehensive Anesthesiology 2021 analysis, only 11% (4/36) comparing surgical infiltration of liposomal bupivacaine (LB) to standard bupivacaine HCl showed a clinically relevant benefit, and manufacturer-related financial conflicts were associated with higher odds of reporting positive pain outcomes (OR 14.3101).[1][2] The CLEVELAND trial (online December 2025; print March 2026) found no significant opioid or pain-score differences between its pre-incision four-quadrant TAP regimens. That result applies to the studied mixed abdominal-surgery population, not every block or operation.[9]

This article is the drug-class pharmacology hub — formulation, preparation rules (they matter), FDA-approved doses and indications, comparison evidence vs standard bupivacaine in infiltration, TAP, and urologic contexts, and cost. For the broader local-anesthetic class (lidocaine, ropivacaine, standard bupivacaine across 12 urologic use cases) see Local anesthetics. For ERAS workflow context see ERAS.

Pharmacology​

Formulation​

Multivesicular liposomes — microscopic honeycomb-like lipid-based particles with multiple aqueous chambers separated by lipid bilayers. Upon injection, liposomes gradually erode and release bupivacaine over an extended period. Like all amide-type local anesthetics, released bupivacaine blocks sodium channels → inhibited nerve impulse generation and conduction.[3][4]

Pharmacokinetics​

ParameterDetail
AbsorptionDepends on total dose, route, vascularity. Systemic plasma levels observed for 96 h after local infiltration, 120 h after interscalene block, 168 h after sciatic / adductor-canal block[4]
Protein binding95% (plasma)
DistributionHighly perfused organs; crosses placenta (F/M ratio 0.2–0.4)
MetabolismHepatic metabolism of bupivacaine — caution in hepatic disease
Systemic levelsDo not correlate with local efficacy

FDA-Approved Indications & Dosing​

IndicationDoseVolumeAge
Local infiltration (adults)Up to 266 mg (20 mL of 1.3%)Dilute with NS or LR up to 1:14 (final concentration ≥ 0.89 mg/mL)≥ 18 yr
Local infiltration (pediatric)4 mg/kg (max 266 mg)Same dilution rulesLabel dosing subsection: 6 to <17 yr
Interscalene brachial plexus block133 mg (10 mL)10 mLAdults
Sciatic nerve block (popliteal fossa)133 mg (10 mL)10 mLAdults
Adductor canal block133 mg + 50 mg bupivacaine HCl 0.5% (10 mL each = 20 mL total)20 mLAdults

Source: current US EXPAREL label. Infiltration is indicated from age 6; the pediatric dosing subsection specifies ages 6 to less than 17, so confirm adolescent dosing rather than extending a table by assumption. TAP blocks are not among the three labeled perineural indications. EXPAREL is not dose-interchangeable with standard bupivacaine.[4]

Preparation and Drug-Interaction Rules — Critical and Unique​

Preparation rules specific to liposomal bupivacaine. These rules are different from standard bupivacaine and are the most common source of drug-waste and lost sustained-release effect.

  • Do NOT admix with non-bupivacaine local anesthetics. Bupivacaine HCl may be given in the same syringe or immediately before EXPAREL when the bupivacaine HCl:EXPAREL milligram ratio does not exceed 1:2; this is not restricted to adductor-canal block. Toxicity is additive, and site-specific dose limits still apply. Lidocaine and other non-bupivacaine locals cause immediate release of encapsulated bupivacaine → the sustained-release mechanism is destroyed.[4]
  • Lidocaine may be administered ≥ 20 min BEFORE liposomal bupivacaine at the same site. Other non-bupivacaine locals — no data supporting pre-administration.
  • Avoid additional local anesthetics within 96 h after EXPAREL; this warning is not limited to the same site. Reconcile the entire anesthetic plan, including label-permitted immediate-release adjuncts for the indicated nerve blocks, with anesthesia/pharmacy.
  • Do NOT dilute with water or hypotonic agents — disrupts liposomal particles. Use 0.9% preservative-free NS or LR only.
  • Use a 25-gauge or larger needle to preserve particle integrity.
  • Invert vial multiple times to re-suspend particles immediately before withdrawal.
  • Use diluted product within 4 h of preparation.
  • Methemoglobinemia risk with concurrent nitrates/nitrites, other local anesthetics, dapsone, sulfonamides, antimalarials, or acetaminophen.[4]

Evidence — Infiltration vs Standard Bupivacaine​

The most-studied comparison and the most consistently negative signal in local-anesthesia literature.

SourceFinding
Ilfeld 2021 Anesthesiology comprehensive review of 76 RCTsOnly 11% (4/36) of surgical-infiltration RCTs showed clinically relevant benefit vs standard bupivacaine. 92% (11/12) of trials showed peripheral nerve block with standard bupivacaine is superior to infiltrated LB. Among low-risk-of-bias trials, only 14% (4/28) reported significant differences — vs 84% (16/19) of high-risk-of-bias trials[1]
Ji 2021 J Surg Res SR of 63 RCTs, n = 6,770LB did not demonstrate significant pain relief in 74.6% of RCTs; no opioid reduction in 85.7% overall (83.3% vs standard bupivacaine). Financial COI association: OR 14.31 for pain (p = 0.0001), OR 12.35 for opioid reduction (p = 0.024). 47.5% of 265 registered RCTs withdrawn / terminated / suspended / unpublished — substantial publication bias[2]
Dinges 2021 RAPM meta + trial sequential analysis, 23 RCTs, n = 1,867Pain ↓ 0.37 points on 10-point scale at 24 h (p < 0.05) — statistically significant, below the 1-point MCID. 15% morphine-equivalent ↓ at 24 h. No significant pain difference at 72 h[5]
Hamilton 2017 CochraneLower cumulative 0–72 h pain vs placebo (very-low-certainty); no difference vs standard bupivacaine (very-low-certainty)[6]
Sandhu 2021 JAMA Network Open RCT, n = 280, truncal incisionsNo benefit over standard bupivacaine[7]
Saad Sayed 2025 meta (8 RCTs, n = 810, abdominal surgery)No significant pain score difference POD 0, 1, 2, 3. No morphine reduction any day. LB not superior to standard bupivacaine in the surgical plane for abdominal procedures[8]

Bottom line — infiltration: the statistically significant 0.37-point pain-score reduction at 24 h falls below the MCID, the signal fades by 72 h, and manufacturer-related financial conflicts were associated with higher odds of a positive result (OR 14.31), not a proven causal or 14-fold probability effect.

Evidence — TAP Blocks​

Particularly relevant for the reconstructive urologist — TAP blocks are a standard ERAS adjunct for major abdominopelvic surgery.

CLEVELAND — 2025 online / 2026 print[9]​

Triple-blinded 3-arm RCT (n = 261) comparing LB plus plain bupivacaine TAP vs plain bupivacaine TAP vs saline placebo TAP for major abdominal surgery:

  • Opioid consumption 0–24 h: 26 MME (LB) vs 33 MME (plain bupivacaine) vs 31 MME (saline) — no significant differences
  • 24–48 h opioid consumption: comparable
  • Pain scores at 24, 48, 72 h: similar across all arms
  • Authors' conclusion: single-shot four-quadrant TAP with LB, plain bupivacaine, or normal saline produced similar postoperative opioid consumption and pain scores

The trial questions routine pre-incision four-quadrant TAP in this mixed surgical population. A nonsignificant difference does not prove equivalence or establish that all TAP approaches lack benefit.

EXPLANE 2022[10]​

Multicenter RCT (n = 498 analyzed), LB TAP vs continuous epidural for major abdominal surgery; stopped at a prespecified futility boundary:

  • Pain at rest: TAP non-inferior to epidural (difference 0.09 points; p < 0.05 for non-inferiority)
  • Less hypotension with TAP (31% vs 48%)
  • More opioid with TAP (+21 mg over 3 days); pain noninferiority should not be read as noninferiority on both coprimary outcomes
  • Important for cystectomy / major-reconstruction patients who are often volume-depleted post-op

Hussain 2024 Anesthesiology meta[11]​

Abdominal fascial-plane blocks, LB vs plain local anesthetics: primary outcome (AUC pain 24–72 h) not different (SMD −0.21; p = 0.058). Robust to COI- and mixing-with-plain-bupivacaine subgroup. Authors: does not support evidence-based preference for LB.

Evidence — Urologic Surgery Specifically​

Radical cystectomy with diversion​

StudyDesignFinding
Chu 2021 (retrospective cohort)LB infiltration vs epidural at fascial closureLB: shorter LOS (4.9 vs 5.9 d); less opioid; lower cost. Confounded by epidural-related hypotension and immobility[12]
Schmidt 2021 (prospective comparison)LB infiltration vs standard bupivacaine infiltrationNo difference in PACU opioid (9.0 vs 6.5 MED; p = 0.29), hospital opioid (36.8 vs 42.1 MED; p = 0.81), POD 1/2/3 pain scores, or LOS (5.0 vs 4.9 d). Authors: "no significant difference"[13]

The retrospective epidural comparison is vulnerable to changes in care and patient selection. Hypotension or mobility differences are possible explanations, not proven mediators. The direct formulation comparison did not detect benefit over standard bupivacaine; it does not prove exact equivalence.

Laparoscopic / robotic urologic surgery​

Knight 2015 RCT (n = 206): LB vs 0.25% bupivacaine — no difference in total opioid (15 vs 17.3 mg MME; p = 0.39), pain scores, LOS, or time to first opioid. "No significant difference between liposomal bupivacaine and 0.25% bupivacaine."[14]

Surgeon-administered TAP in cystectomy​

Roebuck 2022 (n = 178) — a retrospective cohort comparing surgeon-administered TAP with no TAP, found an association with lower POD 0–3 opioid use (106.4 vs 192.2 MME4) and shorter LOS (5.6 vs 7.7 d) — this does not establish causation or prove that location matters more than formulation.[15]

Quality of Recovery — The Most Favorable Signal​

Zhang 2025 meta (11 RCTs, n = 1,357) — the strongest positive evidence for LB, focused on patient-centered recovery outcomes:[18]

  • Quality of Recovery (QoR) at 72 h: SMD 0.52 (95% CI 0.20–0.85)
  • ↓ pain scores at 24, 48, 72 h
  • ↓ cumulative opioid within 72 h
  • ↓ PONV
  • ↑ patient satisfaction

Interpretation: the analgesic advantage on traditional pain scales is small-to-none, but the overall recovery experience may be improved. Weigh against cost and the industry-bias concerns in the broader literature.

Cost​

EXPAREL acquisition cost is generally higher than generic bupivacaine; use local pharmacy prices rather than a fixed national per-vial estimate.

  • Hamilton 2022 JAMA Surgery (knee replacement) — LB dominated by standard bupivacaine (less effective, more costly); only 37% probability of cost-effectiveness at £20,000/QALY threshold.[17]
  • Babazade 2019 cost-effectiveness analysis — IVPCA was most cost-effective; TAP + LB narrowly dominated; epidural clearly dominated.[16]

Cost-effectiveness is procedure- and comparator-specific. Limited evidence of routine clinical superiority should be considered alongside local cost.

Safety Profile​

EXPAREL retains serious bupivacaine toxicity risks and has formulation-specific compatibility restrictions; trials cannot establish that serious harms are absent.[4][6]

  • Common (≥ 10%): nausea, constipation, vomiting
  • Cardiovascular toxicity: same risk as all bupivacaine formulations — cardiac arrest, ventricular arrhythmias, collapse. Monitor CV and neurologic status during and after injection.
  • CNS toxicity: restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, convulsions, unconsciousness, respiratory depression
  • Methemoglobinemia with concurrent methemoglobin-inducing agents
  • Hepatic impairment — caution (amide-type, hepatically metabolized)
  • Chondrolysis risk — not approved for intra-articular use
  • Obstetrical paracervical block is contraindicated. Pregnancy has inadequate safety data and is not recommended by the label.
  • Not recommended routes: epidural, intrathecal, intravascular or intra-articular administration; other perineural blocks are not established labeled indications

For the LAST (Local Anesthetic Systemic Toxicity) framework and 20%-lipid-emulsion rescue protocol, see Local anesthetics.

Evidence Summary​

Clinical questionEvidenceStrength
LB infiltration vs standard bupivacaine infiltrationNo clinically meaningful superiority in 89% of RCTs; ↓ pain 0.37 pts at 24 h (below MCID)Strong — 76+ RCTs, multiple meta-analyses[1][2][5][6]
LB TAP block vs standard bupivacaine TAP vs salineCLEVELAND — no significant differences in the tested regimensStrong — RCT[9]
LB TAP vs epiduralNon-inferior pain; less hypotension (31% vs 48%); slightly more opioidModerate — EXPLANE RCT[10]
LB in radical cystectomyRetrospective benefit versus epidural; no detected benefit versus standard bupivacaineLow–moderate[12][13]
LB in laparoscopic / robotic urologyNo benefit over standard bupivacaineModerate — Knight 2015 RCT[14]
Cost-effectivenessDominated in knee replacement; narrowly dominated by IVPCA for abdominal surgeryModerate[16][17]
Financial COIHigher odds of positive pain outcomes (OR 14.31)Strong — SR[2]
Quality of recoveryModest advantage in patient-centered measuresModerate — 2025 meta[18]

Practical Pearls​

  • The preponderance of evidence does not support routine use of liposomal bupivacaine over standard bupivacaine in wound infiltration or TAP for reconstructive / urologic surgery. Among the 36 surgical-infiltration comparisons in the 76-RCT review, 4 (11%) demonstrated a clinically relevant benefit; that percentage is not the denominator for every studied indication.[1][5]
  • Financial COI is a major interpretive concern — industry-affiliated studies are Higher odds of positive pain outcomes (OR 14.31).[2]
  • CLEVELAND found similar outcomes among the three tested regimens; avoid extending this null result to all surgery-specific TAP protocols.[9]
  • In radical cystectomy-with-diversion, LB infiltration appears better than epidural in retrospective data (probably a hypotension / immobility confounder) but is not different from standard bupivacaine head-to-head.[12][13]
  • LB TAP may be a reasonable alternative when epidural is contraindicated — EXPLANE showed non-inferior pain with significantly less hypotension (31% vs 48%), clinically relevant in volume-depleted cystectomy patients.[10]
  • Preparation rules matter. Lidocaine admixture (or within 20 min of LB at the same site) destroys the sustained-release mechanism. Hypotonic dilution disrupts liposomal particles. Use a 25-gauge or larger-bore needle and NS or LR only.[4]
  • 96-hour warning applies to additional local-anesthetic exposure, not just the injection site.[4]
  • Check local cost and procedure-specific benefit. Historical cost-effectiveness results from knee and abdominal surgery are not a universal price or economic conclusion.[16][17]
  • Quality-of-recovery data (2025) are the most favorable signal for LB — worth knowing about, but should be weighed against the broader evidence base and industry-bias concerns.[18]

See Also​

  • Local anesthetics — parent class hub covering 12 urologic use cases, LAST protocol, standard bupivacaine / lidocaine / ropivacaine dosing
  • NSAIDs & analgesics — opioid-sparing multimodal context
  • ERAS — enhanced-recovery protocol in which TAP blocks and wound infiltration sit
  • Postoperative constipation & ileus — the downstream benefit of opioid-sparing analgesia

References​

1. Ilfeld BM, Eisenach JC, Gabriel RA. "Clinical effectiveness of liposomal bupivacaine administered by infiltration or peripheral nerve block to treat postoperative pain." Anesthesiology. 2021;134(2):283–344. doi:10.1097/ALN.0000000000003630

2. Ji YD, Harris JA, Gibson LE, McKinley SK, Phitayakorn R. "The efficacy of liposomal bupivacaine for opioid and pain reduction: a systematic review of randomized clinical trials." J Surg Res. 2021;264:510–533. doi:10.1016/j.jss.2021.02.024

3. Prabhakar A, Ward CT, Watson M, et al. "Liposomal bupivacaine and novel local anesthetic formulations." Best Pract Res Clin Anaesthesiol. 2019;33(4):425–432. doi:10.1016/j.bpa.2019.07.012

4. EXPAREL. US prescribing information, revised November 2023; DailyMed record updated December 2025. Current label.

5. Dinges HC, Wiesmann T, Otremba B, et al. "The analgesic efficacy of liposomal bupivacaine compared with bupivacaine hydrochloride for the prevention of postoperative pain: a systematic review and meta-analysis with trial sequential analysis." Reg Anesth Pain Med. 2021;46(6):490–498. doi:10.1136/rapm-2020-102427

6. Hamilton TW, Athanassoglou V, Mellon S, et al. "Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain." Cochrane Database Syst Rev. 2017;2:CD011419. doi:10.1002/14651858.CD011419.pub2

7. Sandhu HK, Miller CC, Tanaka A, Estrera AL, Charlton-Ouw KM. "Effectiveness of standard local anesthetic bupivacaine and liposomal bupivacaine for postoperative pain control in patients undergoing truncal incisions: a randomized clinical trial." JAMA Netw Open. 2021;4(3):e210753. doi:10.1001/jamanetworkopen.2021.0753

8. Saad Sayed M, Rath S, Rasool W, et al. "Efficacy of liposomal bupivacaine versus standard bupivacaine following abdominal surgeries: a systematic review and meta-analysis of randomized controlled trials." Pain Pract. 2025;25(5):e70048. doi:10.1111/papr.70048

9. Turan A, Esa WAS, Brooker J, et al. "Liposomal bupivacaine, plain bupivacaine, and saline for transversus abdominis plane blocks: the CLEVELAND randomized trial." Anesthesiology. 2026;144(3):546–558. Published online December 2025. doi:10.1097/ALN.0000000000005869

10. Turan A, Cohen B, Elsharkawy H, et al. "Transversus abdominis plane block with liposomal bupivacaine versus continuous epidural analgesia for major abdominal surgery: the EXPLANE randomized trial." J Clin Anesth. 2022;77:110640. doi:10.1016/j.jclinane.2021.110640

11. Hussain N, Speer J, Abdallah FW. "Analgesic effectiveness of liposomal bupivacaine versus plain local anesthetics for abdominal fascial plane blocks: a systematic review and meta-analysis of randomized trials." Anesthesiology. 2024;140(5):906–919. doi:10.1097/ALN.0000000000004932

12. Chu CE, Law L, Zuniga K, et al. "Liposomal bupivacaine decreases postoperative length of stay and opioid use in patients undergoing radical cystectomy." Urology. 2021;149:168–173. doi:10.1016/j.urology.2020.11.036

13. Schmidt B, Bhambhvani HP, Greenberg DR, et al. "Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: does formulation matter?" Urol Oncol. 2021;39(6):369.e1–369.e8. doi:10.1016/j.urolonc.2020.11.008

14. Knight RB, Walker PW, Keegan KA, et al. "A randomized controlled trial for pain control in laparoscopic urologic surgery: 0.25% bupivacaine versus long-acting liposomal bupivacaine." J Endourol. 2015;29(9):1019–1024. doi:10.1089/end.2014.0769

15. Roebuck E, Beano H, Robinson M, et al. "Surgeon-administered transversus abdominis plane (TAP) block is associated with decreased opioid usage and length of stay following radical cystectomy." Urology. 2022;161:135–141. doi:10.1016/j.urology.2021.11.023

16. Babazade R, Saasouh W, Naylor AJ, et al. "The cost-effectiveness of epidural, patient-controlled intravenous opioid analgesia, or transversus abdominis plane infiltration with liposomal bupivacaine for postoperative pain management." J Clin Anesth. 2019;53:56–63. doi:10.1016/j.jclinane.2018.10.003

17. Hamilton TW, Knight R, Stokes JR, et al. "Efficacy of liposomal bupivacaine and bupivacaine hydrochloride vs bupivacaine hydrochloride alone as a periarticular anesthetic for patients undergoing knee replacement: a randomized clinical trial." JAMA Surg. 2022;157(6):481–489. doi:10.1001/jamasurg.2022.0713

18. Zhang L, Yang S, Liu X, et al. "Impact of liposomal bupivacaine on subjective recovery quality after surgery: a meta-analysis of randomized controlled trials." Front Med. 2025;12:1655756. doi:10.3389/fmed.2025.1655756